Dr. Seely is an endocrinologist with over 20 years of drug development and biopharmaceutical company leadership experience. Dr. Seely was name Chief Executive Officer of Myovant in Month, year. Prior to joining Myovant, Lynn served at Medivation as Chief Medical Officer from 2005-2015 and led the development of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer from IND-enabling studies through to NDA approval and post-approval clinical studies. Previously, she served as vice president of clinical development at Corgentech, Inc. (Anesiva, Inc.), a biomedical company, and as vice president of clinical development at ProDuct Health, Inc., a privately-held medical device company. Dr. Seely began her career in industry at Chiron Corporation. She has led teams running clinical trials in all phases of development in a variety of therapeutic indications. Dr. Seely currently serves on the Board of Directors of Blueprint Medicines. She earned an M.D. Alpha Omega Alpha from the University of Oklahoma, College of Medicine and completed her residency in internal medicine at Yale-New Haven Hospital and a basic science and clinical fellowship in endocrinology and metabolism at the University of California, San Diego. She earned a Bachelor of Arts degree from the University of Oklahoma.